24.02.2010 AbD Serotec Significantly Improves Antibody Generation Process

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) ) today announced that its research and diagnostic antibody unit AbD Serotec has demonstrated significant progress using the HuCAL-based technology platform ...
 

18.02.2010 MorphoSys and Galapagos Expand Antibody Alliance
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and Galapagos NV (Euronext: GLPG) announce that they have expanded their antibody alliance in bone and joint diseases.  Based on the solid progress made so far, the partners have agreed to add another antibody target to the alliance, thereby increasing the total number of programs to four.

17.02.2010 BioVaria Goes Europe: Marketplace for Life-Science Inventions from Leading European Research Institutions
Ascenion GmbH and its partners are pleased to announce the forthcoming BioVaria 2010, to be held in Munich on 20 April 2010. BioVaria is the only dedicated biopharmaceutical showcasing event that presents licensing opportunities and spin-off projects from leading research institutions and universities from all over Europe to the biopharmaceutical industry.